Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 1

A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors

NCT07159828 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to learn more about the side effects and best dose of AXN-2510 in adults with advanced solid tumors. The main questions it aims to answer are: * What are the side effects of AXN-2510? * Which is the best tolerated dose of AXN-2510? * How long does AXN-2510 stay in your body? Participants will receive AXN-2510 every 3 weeks. Participants will visit the clinic for checkups and tests several days during the first and third doses, and once every 3 weeks for other doses.

Conditions Studied

Interventions

  • BIOLOGICAL AXN-2510

Study Locations (7)

Texas

  • Sarah Cannon Research Institute at Mary Crowley — Dallas
  • New Experimental Therapeutics (NEXT) Oncology - Houston — Houston
  • NEXT Houston — Houston
  • New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio
  • NEXT San Antonio — San Antonio

North Carolina

  • Carolina BioOncology — Huntersville

Virginia

  • NEXT Virginia — Fairfax

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2025-09-15
Est. Completion 2027-05-15
Phase Phase 1

Sponsor

Axion Bio

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07159828

The ClinicalTrials.gov registry entry for NCT07159828 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axion Bio, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention — of which AXN-2510 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07159828 reports 7 study locations spanning 3 distinct geographic areas — top geographies include Texas, North Carolina, Virginia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07159828 about?

NCT07159828 is a clinical study titled "A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors". The goal of this clinical trial is to learn more about the side effects and best dose of AXN-2510 in adults with advanced solid tumors. The main questions it aims to answer are: * What are the side effects of AXN-2510? * Which is the best tolerated dose of AXN-2510? * How long does AXN-2510 stay in...

What is the current status of trial NCT07159828?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2025-09-15. Estimated completion is 2027-05-15.

What conditions does trial NCT07159828 study?

This clinical trial studies the following conditions: Solid Tumor, Adult. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07159828?

The interventions under investigation include: AXN-2510 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07159828?

This trial is sponsored by Axion Bio, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07159828 being conducted?

This trial has 7 study locations across North Carolina, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial